Clinical Trials Logo

NSCLC Stage IV clinical trials

View clinical trials related to NSCLC Stage IV.

Filter by:

NCT ID: NCT04166487 Active, not recruiting - NSCLC Stage IV Clinical Trials

Plasma-Adapted First-Line Pembro In NSCLC

Start date: January 13, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and use that information to determine whether patients should continue treatment with pembrolizumab or switch treatment to pembrolizumab in combination with chemotherapy. The names of the study drugs involved in this study are: - Pembrolizumab - Platinum doublet chemotherapy, which may include the following: - Carboplatin and pemetrexed - Carboplatin and paclitaxel The name of the blood test: - InVision (Inivata, Ltd.)

NCT ID: NCT04136535 Not yet recruiting - NSCLC Stage IV Clinical Trials

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

PCA
Start date: October 18, 2019
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced Osimertinib-resistant non-squamous non-small cell lung cancer.

NCT ID: NCT04116918 Recruiting - NSCLC Stage IV Clinical Trials

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

Start date: September 1, 2019
Phase:
Study type: Observational

This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.

NCT ID: NCT04106180 Recruiting - NSCLC Stage IV Clinical Trials

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

Start date: September 30, 2019
Phase: Phase 2
Study type: Interventional

This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients with advanced NSCLC.

NCT ID: NCT04102982 Recruiting - NSCLC Stage IV Clinical Trials

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

MWA in NSCLC
Start date: November 1, 2019
Phase: Phase 2
Study type: Interventional

Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.

NCT ID: NCT04082988 Terminated - NSCLC, Stage IV Clinical Trials

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

Start date: January 23, 2018
Phase: N/A
Study type: Interventional

A pilot study with biomarker exploration.50 patients with stage IV non-small cell lung cancer (NSCLC) that are eligible for treatment with nivolumab. Patients will undergo a 18F-FDG-PET/CT and EBUS-FNA of the lymph nodes and have blood drawn before and after immune checkpoint inhibitor treatment to compare tumor FDG uptake and to identify changes in the immune effector cell subsets in TDLNs. Blood will be drawn in parallel to compare the distribution of immune effector cell subsets before and after treatment initiation. Because of the possible burden for patients, the EBUS-FNA is not mandatory to complete the study and is there for an exploratory objective. Also blood will be drawn for a tumor mutational burden at baseline. The first six patients will undergo a dynamic PET-CT scan in addition to a static scan to study the influence of possible immunotherapy induced changes to the body distribution and kinetics of FDG..

NCT ID: NCT04076228 Completed - NSCLC Stage IV Clinical Trials

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

Start date: January 1, 2017
Phase:
Study type: Observational

Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China. The investigators hypothesize CD38 expressing cells and/or other immune populations will help to predict response.

NCT ID: NCT04042558 Recruiting - NSCLC Stage IV Clinical Trials

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

GFPC 06-2018
Start date: September 26, 2019
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

NCT ID: NCT04027647 Active, not recruiting - NSCLC Stage IV Clinical Trials

Phase 2 Study of Dacomitinib in NSCLC

Start date: September 11, 2019
Phase: Phase 2
Study type: Interventional

This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage IIIB/IIIC/IV or recurrent EGFR-mutation-positive non-small cell lung cancer (NSCLC). National Cancer Centre Singapore is the lead sponsor acting in a coordinating capacity and the rest of the participating sites are sponsors of their own individual sites.

NCT ID: NCT03960034 Completed - NSCLC Stage IV Clinical Trials

Cachexia in NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional and Skeletal Muscle Implications

LUCAX01
Start date: April 10, 2017
Phase:
Study type: Observational

LUCAX01 is a cohort study with patients with advanced NSCLC in tobacco users. in this study, patients will be submitted to baseline physical tests, blood and biopsy sample collection, and the main objective is to study the functional and prognostic implications of cachexia and to validate skeletal muscle dysfunction markers.